User profiles for M. Ranson
 | Marie RansonSchool of Chemistry and Molecular Bioscience, University of Wollongong Verified email at uow.edu.au Cited by 6346 |
Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008
Isatin (1H-indole-2,3-dione) and its derivatives demonstrate a diverse array of biological and
pharmacological activities including anticonvulsant, antibacterial, antifungal, antiviral and …
pharmacological activities including anticonvulsant, antibacterial, antifungal, antiviral and …
DT-diaphorase: a target for new anticancer drugs
S Danson, TH Ward, J Butler, M Ranson - Cancer treatment reviews, 2004 - Elsevier
DT-diaphorase (DTD) is an obligate two-electron reductase which bioactivates chemotherapeutic
quinones. DTD levels are elevated in a number of tumour types, including non-small …
quinones. DTD levels are elevated in a number of tumour types, including non-small …
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
The development of therapeutic resistance to targeted anticancer therapies remains a
significant clinical problem, with intratumoral heterogeneity playing a key role. In this context, …
significant clinical problem, with intratumoral heterogeneity playing a key role. In this context, …
[HTML][HTML] AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer
…, PA Dickinson, S Ghiorghiu, M Ranson - … England Journal of …, 2015 - Mass Medical Soc
Background The EGFR T790M mutation is the most common mechanism of drug resistance
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
…, GHP Richmond, M Cantarini, DW Kim, MR Ranson… - Cancer discovery, 2014 - AACR
First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm + ) non–small cell lung cancer (NSCLC)…
benefit in patients with advanced EGFR-mutant (EGFRm + ) non–small cell lung cancer (NSCLC)…
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …
J Baselga, D Rischin, M Ranson, H Calvert… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic …
growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic …
[PDF][PDF] Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer
Purpose Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell
lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study …
lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study …
ZD1839, a selective oral epidermal growth factor receptor–tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a …
M Ranson, LA Hammond, D Ferry, M Kris… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral,
selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with …
selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with …
[HTML][HTML] Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
…, D Jowle, M Brampton, G Halbert, M Ranson - British journal of …, 2004 - nature.com
… mg m −2 and above. Dose-related myelosuppression was seen and DLT (neutropenic sepsis)
was reached at 90 mg m −2 . The MTD of SP1049C defined in this study was 70 mg m −2 . …
was reached at 90 mg m −2 . The MTD of SP1049C defined in this study was 70 mg m −2 . …
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer
…, D Khaira, SS Ramalingam, MR Ranson… - Clinical Cancer …, 2012 - AACR
Purpose: Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small
cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 …
cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 …